Combination strategies for pain management.

Abstract:

:At least two factors relating to pain management using oral analgesics suggest that combination strategies merit consideration: many pains arise from more than one physiological cause and current analgesics have adverse effect profiles that might be reduced by combination with another agent in smaller doses or with less frequent dosing. In addition to increased convenience, combinations sometimes also result in the unexpected benefit of synergy. But not all pains, clinical settings or combinations merit the extra expense or other potential negative features of fixed-ratio products. This review examines the multiple basic science, clinical and pharmacoeconomic issues relating to analgesic combinations and the methodologies available for assessing these issues.

authors

Raffa RB,Clark-Vetri R,Tallarida RJ,Wertheimer AI

doi

10.1517/14656566.4.10.1697

keywords:

subject

Has Abstract

pub_date

2003-10-01 00:00:00

pages

1697-708

issue

10

eissn

1465-6566

issn

1744-7666

journal_volume

4

pub_type

杂志文章,评审
  • Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: a prospective observational study.

    abstract::Pancreatic cancer has one of the worst prognosis of any malignant disease. Systemic therapy is often administered because the disease is usually detected at advanced stages. Gemcitabine (Gemzar trade mark, Eli Lilly & Co.) has proven activity in the treatment of pancreatic cancer. Gemcitabine 1000 mg/m(2) was given on...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.4.581

    authors: Karasek P,Skacel T,Kocakova I,Bednarik O,Petruzelka L,Melichar B,Bustova I,Spurny V,Trason T

    更新日期:2003-04-01 00:00:00

  • Does antipsychotic combination therapy reduce the risk of hospitalization in schizophrenia?

    abstract:INTRODUCTION:: Despite treatment with antipsychotic medication, approximately 1/3 of individuals with schizophrenia will fail to have an adequate response. To treat these patients, a commonly utilized approach is antipsychotic combination therapy. Antipsychotic combination therapy is controversial with mixed efficacy a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1847274

    authors: Faden J,Kiryankova-Dalseth N,Barghini R,Citrome L

    更新日期:2020-11-30 00:00:00

  • Efficacy of lenvatinib in treating thyroid cancer.

    abstract:INTRODUCTION:Radioiodine [RAI]-resistant advanced and progressive differentiated thyroid cancer [DTC], although rare, constitutes a real challenge as its prognosis is poor and available therapeutic options, until now, have been limited. Discovery of a crucial role of distinct tyrosine kinases in DTC pathogenesis opened...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2016.1206078

    authors: Krajewska J,Kukulska A,Jarzab B

    更新日期:2016-08-01 00:00:00

  • Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.

    abstract:INTRODUCTION:Docetaxel and paclitaxel are among the most active agents for the treatment of breast cancer. These first-generation taxanes are extremely hydrophobic; therefore, solvents are needed for its parenteral administration. Albumin nanoparticle technology allows for the transportation of such hydrophobic drugs w...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.651127

    authors: Guarneri V,Dieci MV,Conte P

    更新日期:2012-02-01 00:00:00

  • Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.

    abstract:INTRODUCTION:Immune-checkpoint inhibitor (ICPI) drugs, which include antibodies against CTLA-4, PD-1 and PD-L1, have been shown to induce durable complete responses in a proportion of patients with particular efficacy demonstrated in both the first line and refractory setting in advanced NSCLC and melanoma. However, th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1369956

    authors: Flynn MJ,Larkin JMG

    更新日期:2017-10-01 00:00:00

  • The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial.

    abstract::A randomized Phase III trial tested the efficacy of pemetrexed as maintenance treatment in patients with advanced non-small-cell lung cancer (NSCLC) who were without progression after completing four cycles of first-line platinum-based chemotherapy. The primary endpoint of the trial was progression-free survival (PFS)...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1517/14656560903485672

    authors: Gridelli C,Di Maio M

    更新日期:2010-02-01 00:00:00

  • The impact of daily sildenafil on levels of soluble molecular markers of endothelial function in plasma in patients with erectile dysfunction.

    abstract:OBJECTIVE:To investigate the impact of daily sildenafil on levels of soluble molecular markers of endothelial function in men with erectile dysfunction. METHODS:Patients aged >18 years with erectile dysfunction of vascular etiology for >6 months, either alone or in combination with disease states strongly associated w...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656560802678211

    authors: Konstantinopoulos A,Giannitsas K,Athanasopoulos A,Spathas D,Perimenis P

    更新日期:2009-02-01 00:00:00

  • Hydrochlorothiazide: is it a wise choice?

    abstract:INTRODUCTION:Hydrochlorothiazide (HCTZ) has not been shown to reduce mortality or cardiovascular events when given as a single agent. In fact, HCTZ increased cardiovascular death and coronary artery disease (CAD) compared to placebo and usual care in 2 randomized trials, yet it is the most prescribed diuretic in the Un...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.670636

    authors: DiNicolantonio JJ

    更新日期:2012-04-01 00:00:00

  • Therapeutic options for HIV-associated lymphomas.

    abstract:IMPORTANCE OF THE FIELD:The clinical features and natural history of HIV-associated lymphomas differ greatly from those observed in the general population. The failure to improve outcomes with treatment intensification indicates the need for the introduction of new therapeutic options. AREAS COVERED IN THIS REVIEW:Thi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2010.502528

    authors: Spina M,Gloghini A,Tirelli U,Carbone A

    更新日期:2010-10-01 00:00:00

  • Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma.

    abstract:IMPORTANCE OF THE FIELD:The emergence of fixed-combination drugs for the treatment of glaucoma has, to some extent, changed the medical management of glaucoma. The potential benefits of these drugs include a reduction in the total number of drops and preservatives instilled per day and improved patient comfort factors,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656561003667540

    authors: Razeghinejad MR,Sawchyn AK,Katz LJ

    更新日期:2010-04-01 00:00:00

  • Colesevelam HCl: a non-systemic lipid-altering drug.

    abstract::Colesevelam HCl (WelChol, Sankyo Pharmaceuticals Inc.) is a bile acid sequestrant polymer, which has been shown to significantly lower low density lipoprotein cholesterol and favourably affect high-density lipoprotein cholesterol blood levels in monotherapy and in combination with statins (HMG-CoA reductase inhibitors...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.5.779

    authors: Bays H,Dujovne C

    更新日期:2003-05-01 00:00:00

  • Advances in pharmacotherapy for hyperphosphatemia in renal disease.

    abstract:INTRODUCTION:Hyperphosphatemia in chronic kidney disease (CKD) is considered as an independent risk factor for surrogate clinical end points like vascular calcification (VC) and bone disease, or hard clinical outcomes like cardiovascular events. Various treatment options are available for phosphate removal or reduction...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1092521

    authors: Spasovski G

    更新日期:2015-01-01 00:00:00

  • Oseltamivir: a clinical and pharmacological perspective.

    abstract::Oseltamivir is the ethyl ester prodrug of the antiviral molecule, oseltamivir carboxylate, a potent and selective inhibitor of influenza A and B neuraminidase (NA) (sialidase). It is highly bioavailable in capsule and suspension formulations and, after conversion to the active metabolite in the liver, distributes thro...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.10.1671

    authors: Doucette KE,Aoki FY

    更新日期:2001-10-01 00:00:00

  • Daclatasvir for the treatment of chronic hepatitis C.

    abstract:INTRODUCTION:Following more than 20 years of Interferon (IFN)-based treatment for hepatitis C virus (HCV), the understanding of viral life cycle led to the development of new antiviral drugs directly targeting HCV replication steps. Daclatasvir (DCV) is a potent inhibitor of non-structural NS5A HCV protein with pangeno...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1109631

    authors: Degasperi E,Aghemo A,Colombo M

    更新日期:2015-01-01 00:00:00

  • A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer.

    abstract::Following Huggins' original observation of the dependence of the prostate on androgens, testosterone suppression by either orchiectomy or oestrogen compounds (e.g., diethylstilbesterol [DES]) became the standard palliative treatment for advanced prostate cancer. Early studies showed testosterone suppression improved s...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.2.447

    authors: Perez-Marrero R,Tyler RC

    更新日期:2004-02-01 00:00:00

  • Oral chemotherapy for the treatment of hepatocellular carcinoma.

    abstract:INTRODUCTION:Many clinical trials have been conducted with chemotherapies in patients with advanced hepatocellular carcinoma (HCC). However, few agents have shown efficacy. It is thought that the efficacy of some agents might have resulted from the heterogeneity of tumors, insufficient dosages due to liver cirrhosis, a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1479398

    authors: Yamamoto S,Kondo S

    更新日期:2018-06-01 00:00:00

  • Is vaccine therapy the future in cancer prevention?

    abstract::One vaccine designed to prevent cancer by preventing a precursor infection is already in common use, and at least one more is in the latter stages of clinical development. These vaccines are part of a new era of cancer immunoprophylaxis. Several further vaccines are in preclinical and clinical development, targeted at...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656566.5.12.2427

    authors: Frazer I

    更新日期:2004-12-01 00:00:00

  • New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.

    abstract:BACKGROUND:Sitagliptin is a highly selective oral dipeptidyl peptidase-4 inhibitor. This drug increases the plasma concentration of active glucagon like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide. These two hormones then simulate the secretion of insulin in a glucose-dependent manner and inhibit glu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.9.1495

    authors: Gagliardino JJ,Santoro S,Arellano S,Di Girolamo G

    更新日期:2008-06-01 00:00:00

  • Current trends in antithyroid drug treatment of Graves' disease.

    abstract:INTRODUCTION:Graves' hyperthyroidism is associated with significant morbidity and mortality risk. The thionamides, methimazole, its pro-drug derivative carbimazole, and propylthiouracil, remain a cornerstone of management. Yet despite decades of use, optimal strategies for maximising treatment response and curtailing a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1232388

    authors: Okosieme OE,Lazarus JH

    更新日期:2016-10-01 00:00:00

  • Vancomycin for treatment of invasive, multi-drug resistant Staphylococcus aureus infections.

    abstract::Staphylococcus aureus is a bacterial pathogen responsible for a variety of serious infections and is a frequent cause of nosocomial disease. During the last 60 years, S. aureus has developed increasing in vitro resistance to virtually all antimicrobials. In contrast, vancomycin has maintained a high degree of activity...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.9.1245

    authors: Pope SD,Roecker AM

    更新日期:2007-06-01 00:00:00

  • Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.

    abstract:INTRODUCTION:In this review, the authors describe medications in phase III of clinical development for schizophrenia and schizoaffective disorder, and provide an opinion on how current treatment can be improved in the near future. AREAS COVERED:Recent (post 2013) phase III clinical trials of schizophrenia-targeted the...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1149164

    authors: Garay RP,Citrome L,Samalin L,Liu CC,Thomsen MS,Correll CU,Hameg A,Llorca PM

    更新日期:2016-01-01 00:00:00

  • The therapeutic management of differentiated thyroid cancer.

    abstract:BACKGROUND:The management of thyroid cancer is difficult because the tumors comprise a wide range of biologic behaviors, from small papillary thyroid microcarcinomas that pose little or no threat to survival for the patient, to anaplastic thyroid cancers that are arguably the most lethal tumor. Although it may be diffi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.15.2627

    authors: Sipos JA,Mazzaferri EL

    更新日期:2008-10-01 00:00:00

  • Current understanding of the role of bosentan in inoperable chronic thromboembolic pulmonary hypertension.

    abstract::Chronic thromboembolic pulmonary hypertension may occur in the context of incomplete lysis of acute pulmonary emboli, resulting in the obstruction of pulmonary blood flow, as well as progressive right ventricular dysfunction and failure. The treatment of choice for this condition is surgical removal of the obstructing...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.9.1133

    authors: Hughes R,Jais X,Suntharalingam J,Humbert M,Parent F,Simonneau G,Pepke-Zaba J

    更新日期:2006-06-01 00:00:00

  • Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis.

    abstract::Osteoporosis is a severe condition, associated with significant disability as a result of fragility fractures and increased mortality. Oral bisphosphonates effectively reduce the risk of osteoporotic fracture and are generally well tolerated. Unfortunately, patient outcomes are often compromised by suboptimal therapeu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.13.2301

    authors: Reginster JY

    更新日期:2005-10-01 00:00:00

  • Fondaparinux versus enoxaparin for the prevention of venous thromboembolism.

    abstract::Venous thromboembolism is a frequent, life-threatening, postoperative complication of hip-fracture and total-knee-replacement surgery. Fondaparinux is a synthetic polysaccharide that selectively binds to antithrombin, the primary endogenous regulator of blood coagulation. Low molecular weight heparins, such as enoxapa...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 评论,杂志文章,评审

    doi:10.1517/14656566.3.4.455

    authors: Doggrell SA

    更新日期:2002-04-01 00:00:00

  • BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma.

    abstract:INTRODUCTION:BRAF inhibition alone has achieved unprecedented efficacy results in patients affected by BRAF-mutated advanced melanoma. Since these findings, it was postulated that dual inhibition of BRAF and other components of the RAS/RAF/MEK/ERK MAPK pathway (such as MEK) would be superior to BRAF inhibition as monot...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1044971

    authors: Richman J,Martin-Liberal J,Diem S,Larkin J

    更新日期:2015-06-01 00:00:00

  • Myelofibrosis: an update on drug therapy in 2016.

    abstract:INTRODUCTION:Primary myelofibrosis (PMF) is the least common but the most aggressive of the classic Philadelphia chromosome-negative myeloproliferative neoplasms. Survival is much shorter in PMF than in polycythemia vera (PV) or essential thrombocythemia (ET). Post-PV/ET myelofibrosis (MF) is clinically indistinguishab...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1252333

    authors: Bose P,Verstovsek S

    更新日期:2016-12-01 00:00:00

  • Comparative evaluation of efficacy and safety of cefotaxime-sulbactam with amoxicillin-clavulanic acid in children with lower respiratory tract infections.

    abstract:OBJECTIVE:Beta-lactamase producing bacteria present a major problem in treating lower respiratory tract infections. The objective of this study was to evaluate efficacy and safety of cefotaxime-sulbactam combination versus amoxicillin-clavulanic acid injection as an alternative therapeutic option for treatment of lower...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1517/14656566.9.16.2751

    authors: Pareek A,Kulkarni M,Daga S,Deshpande A,Chandurkar N

    更新日期:2008-11-01 00:00:00

  • G-CSF as prophylaxis of febrile neutropenia in SCLC.

    abstract:OBJECTIVES:In 1991, small cell lung cancer (SCLC) was reported as the first tumour type where colony stimulating factor (CSF) support was clinically effective. We reviewed 13 health services research studies that addressed CSF use as supportive care for SCLC. METHODS:Findings from American Society of Clinical Oncology...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.9.1273

    authors: Adams JR,Lyman GH,Djubegovic B,Feinglass J,Bennett CL

    更新日期:2002-09-01 00:00:00

  • A review of the clinical efficacy and tolerability of almotriptan in acute migraine.

    abstract::Almotriptan is a serotonin (5-hydroxytryptamine, 5HT)(1B/1D)-receptor agonist approved for the acute treatment of migraine. In 3500 acute migraine patients enrolled in short-term trials and 1500 patients in long-term open-label trials, almotriptan 12.5 mg was effective and well-tolerated. Almotriptan maintains a consi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.7.1157

    authors: Dodick DW

    更新日期:2003-07-01 00:00:00